Immunogenic cell death induced by cytotoxic compounds contributes to the success of selected chemotherapies by eliciting a protective anticancer immune response, which is mediated by CD4 þ and CD8 þ T cells producing interferon-c. In many instances, cancer progression is associated with high titers of tumor-specific antibodies, which become detectable in the serum, but whose functional relevance is elusive. Here, we explored the role of humoral immune responses in the anticancer efficacy of anthracyclines. Chemotherapy reduced the number of tumor-infiltrating B cells, and failed to promote humoral responses against immunodominant tumor antigens. Although anthracycline-based anticancer chemotherapies failed in T cell-deficient mice, they successfully reduced the growth of cancers developing in mice lacking B lymphocytes (due to the injection of a B-celldepleting anti-CD20 antibody), immunoglobulins (Igs) or Ig receptors (Fc receptor) due to genetic manipulations. These results suggest that the humoral arm of antitumor immunity is dispensable for the immune-dependent therapeutic effect of anthracyclines against mouse sarcoma. In addition, we show here that the titers of IgA and IgG antibodies directed against an autoantigen appearing at the cell surface of tumor cells post chemotherapy (calreticulin, CRT) did not significantly increase in patients treated with anthracyclines, and that anti-CRT antibodies had no prognostic or predictive significance. Collectively, our data indicate that humoral anticancer immune responses differ from cellular responses in, thus far, that they do not contribute to the success of anthracycline-mediated anticancer therapies in human breast cancers and mouse sarcomas.
Cancer often results from a chronic inflammatory process, in which multiple hematopoietic and/or immune components participate. 1, 2 The question arises as to which immune cell subset directly or indirectly promote malignancy, and whether these chronic infiltrates are generic across multiple solid tumor types or instead reflect tissue-selective, or oncogenic pathway-selective, profiles. If the contribution of leukocyte populations to oncogenesis or tumor progression was generic, therapeutics aimed at quelling the protumorigenic activities of such subsets could be proposed. Hence, it is of utmost importance to investigate how the interplay between inflammatory cells is orchestrated and modulated during anticancer therapies.
Dendritic cells (DCs) are bone marrow-derived cells that are present in all tissues, 3 where they scan the environment and take up foreign antigens (including tumor antigens) before migrating to lymphoid organs to trigger adaptive immune responses. 3 Upon recognition of a foreign antigen, T and B lymphocytes undergo clonal expansion and mount antigen-specific 'cognate' responses. Once the adaptive immune response has ensued, the source of danger or damage is eliminated, inflammation declines and tissue homeostasis is restored. In tumors, these well-orchestrated series of events fail to resolve and lead to chronic inflammation. Activated leukocytes (mostly represented by myeloid cells) supply direct and indirect mitogenic growth mediators and proteolytic enzymes that stimulate the expansion and dissemination of both neoplastic and stromal cells. 4 Moreover, the chronic presence of paracrine and juxtacrine mitogenic and tissue-remodeling molecules fuels programs that impair antitumor cytotoxic T lymphocyte (CTL) or NK/NKT cellmediated killing of 'damaged' (cancer) cells (reviewed in 5 ). In addition to myeloid cells, lymphocytes has an important role in chronic inflammation. B cells display variable pro-and anti-tumor bioactivities deriving from their functional plasticity and phenotypic heterogeneity. As the sole producers of immunoglobulins (Igs), B cells are critical initiators and modulators of humoral immunity, tailoring specific responses to infections. In addition, B lymphocyte-derived paracrine factors are causative and/or potentiating mechanisms of disease, as shown in autoimmunity. 6 Moreover, there is an accumulating evidence that B-cell function is relevant to carcinogenesis. Cancer patients often develop specific antibody responses against tumor antigens, 6 which are mostly correlated with poor survival. 7 Progression of human papillomavirus type 16 E6/E7-driven squamous carcinogenesis in transgenic mice is significantly diminished in the absence of B cells. 8, 9 In this preclinical tumor model, promotion of the early steps of carcinogenesis is achieved through deposition of IgG autoantibody in the neoplastic parenchyma and immune complex/FcgR ligation of mast cells and macrophages, eventually fostering proangiogenic and immunosuppressive gene expression programs. 8, 9 Similarly, skin chemical carcinogenesis by two-stage application of the DNA damaging agent DMBA and the tumor promoter TPA occurs more rapidly in B-cell-proficient mice than in B-celldeficient mice. 10 As a possibility, B cells may modulate myeloid cell phenotypes through the secretion of IL-10 and TNFa, thereby accelerating tumor progression. Finally, B-cellderived lymphotoxin b is responsible for promoting castration resistance in mice with transgene-induced prostate cancer, likely by stimulating IKKa and STAT3 activity in the malignant cells. 11 Whereas these studies revealed the protumorigenic potential for B cells, others reported no specific functional significance for B cells during mammary carcinogenesis. 12 The efficacy of anticancer therapies is determined by tumor cell-intrinsic as well as by cell-extrinsic, in part immune factors. Thus, therapeutic settings that induce tumor antigenspecific Th1/Tc1 responses (i.e. immune responses that involve specific T cell subsets producing interferon-g) are particularly efficient in eliminating residual tumor cells. The way cancer cells die when exposed to selected chemotherapeutics (such as anthracyclines and oxaliplatin) die, ultimately dictates the immunogenicity of cell death. 'Immunogenic cell death'(ICD) can be defined as a process, in which cell death is preceded by a preapoptotic endoplasmic reticulum (ER) stress response and autophagic program, facilitating the recruitment, activation and antigen-presenting function of DCs. 13 Indeed, ICD is accompanied by exposure or secretion of cell death-associated molecular patterns, such as calreticulin (CRT) (for the engulfment of dead bodies by DC), high-mobility group Box-1 (HMGB1) (for the Toll-like receptor 4/myeloid differentiation primary response genedependent processing of the phagocytic cargo by DC) and ATP (for DC recruitment and the Nlrp3-dependent IL-1b release culminating in Tc1 polarization). 13 Accordingly, after exposure to neoadjuvant chemotherapy, approximately one-third of stage 2/ 3 breast cancers appeared highly infiltrated by cytotoxic T cells, with a concomitant reduction of B lymphocytes and Th2 cells. 14 Moreover, the relative proportions of macrophages and CD8 þ T cells predict the pathological responses to neoadjuvant anthracycline-based therapy and overall survival in locally advanced breast cancer. 15 As conventional chemotherapies can elicit tumor-specific T cell immunity, which then contribute to durably and negatively inflecting the tumor growth curve, we addressed the question whether anticancer therapies would also stimulate B cell-or Fc receptor (FcR)-dependent immune responses. Using a variety of complementary experimental settings, we came to the conclusion that humoral immune responses are not specifically induced by chemotherapy, and that they do not significantly contribute to tumor control.
Results
Intratumoral accumulation of antigen-specific T cells but depletion of B cells after chemotherapy. þ T cells (CTL) that were adoptively transferred into CD45.1 congenic mice on the first day post chemotherapy proliferated and accumulated in tumor beds (Figures 1a and b) . This expansion of OVA-specific T cells reflects a general increase in the frequency of Th1 and Tc1 cells post chemotherapy. 16, 17 In sharp contrast, doxorubicin depleted intratumoral B cells by more than 70% (Figure 1c ). Moreover, a single systemic injection of cyclophosphamide reduced the number of splenic B cells, while it increased the frequency of CTL in the spleen (Supplementary Figures 1A-C) . Thus conventional chemotherapeutic regimens that stimulate local or systemic T cell responses, can reduce the number of B cells.
Contribution of cytotoxic T cells but not of B lymphocytes to the therapeutic effect of anthracyclines.
To further assess the role of B cells, we compared the antitumor effects of doxorubicin on MCA205 cancers established in C57Bl6 WT versus mMT mice, which lack Igs and B lymphocytes. 18 In mMT mice, anthracyclines successfully reduced tumor growth, and this effect was undistinguishable from that observed in the WT control mice ( Figure 2a ). Next, we took advantage of an anti-CD20 antibody, 19 which was applied at different time points pre/post-tumor inoculation and pre/post doxorubicin ( Figure 3a ) to deplete CD19
þ B lymphocytes ( Figure 3b , not shown). B-cell depletion did not affect the natural expansion of MCA205 cells (which lack CD20 expression, not shown) in vivo, and failed to compromise the efficacy of chemotherapy against this MCA205 sarcomas (Figures 3c-e) . In contrast, depletion of CTLs using anti-CD8a antibodies completely abrogated the antitumor effects of anthracyclines (Figures 4a and b) , confirming their contribution to the efficacy of chemotherapy. 13 Hence, genetic deficiency or antibody-induced depletion of B lymphocytes did not interfere with the therapeutic activity of anthracyclines.
No contribution of Igs and Fc receptos to the efficacy of anticancer chemotherapy. To investigate to which extent Igs might modulate the therapeutic efficacy of chemotherapy,
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we analyzed the titers of Ig directed against the immunodominant tumor antigen OVA in our model system. OVA-specific IgG/M/A antibody titers (monitored at day 15 and 21 post therapy) were not boosted by chemotherapy (not shown and Figure 2b ). It is known that leukocyte FcRg is necessary for squamous carcinogenesis, 8 as well as for short and long-term effects (involving memory T cell responses) in the lymphoma bearing mice treated with antibody-dependent cell cytotoxicity (ADCC)-mediating Ab. 20 Therefore, we assessed the putative contribution of FcgR to the efficacy of chemotherapy against MCA205 OVA sarcoma. FcgRs are broadly expressed on immune cells and encompass both activating, for example, FcgRI, III and IV (including the FcRg subunit), and inhibitory, for example, FcgRIIB and subtype complexes. 21 MCA205 OVA was inoculated into the mice genetically manipulated to lack specific FcRg subtypes, namely FcgRIII, 22 FcgRI, 23 FcgRIV, 24 as well as into 'FcgRIV only' mice (which lack FcgRI/IIB/III/FceRI/II genes) 25 or 'FcgRIIB only' mice (which lack the FcgRI/IIIA/IV genes). 26 Thus, anthracyclines similarly reduced tumor growth in these FcRg-deficient mice (Figures 5a-f) , as it did in WT C57Bl6 controls (see above, Figure 2a ). Of note, FcRg does not bind Igs, but is a subunit that mediates signal transduction by other receptors relevant to myeloid cell function, including the macrophage-inducible C-type lectin (Mincle), 27 which has a cardinal role in antimycobacterial responses. 28 In accord with the observation that FcgRIII did not affect anthracycline responses (Figure 5 ), the efficacy of anthracyclines was not compromised in Mincle knock-out mice either (Supplementary Figure 2) .
Altogether, humoral immune responses directed against immunodominant tumor antigens as well as FcR are dispensable for the chemotherapeutic activity of anthracyclines.
Humoral immune responses against ICD-related autoantigens in patients. The chaperone CRT is sequestered in the ER in unstressed cells, but relocates to the plasma membrane upon induction of ER stress by anthracyclines 13 or hypericin-based photodynamic therapy. 29 Its immunohistochemical detection in paraffin-embedded primary breast cancer tissues has been correlated with serum levels of anti-CRT antibodies. 30 We analyzed the titers of IgA and IgG antibodies in 75 healthy controls and 63 breast cancer patients (Table 1, Figure 6a ) at diagnosis, during and after systemic chemotherapy (Figure 6b ). Both anti-CRT IgA and IgG serum levels were slightly higher in (Figure 6a) . However, chemotherapy failed to significantly increase the humoral immune response against CRT (Figure 6b ). Paired serum specimens were available in four cases, revealing no specific increase post therapy (Supplementary Figure 3) . The seroconversion (defined as antibody titers reaching levels above the detection threshold of the ELISA test 30 ) of patients either at diagnosis or after neoadjuvant chemotherapy failed to correlate with the pathological complete responses (Figure 6c ) or metastases-free survival (Figure 6d ). We conclude that in human breast cancer, humoral immune responses directed against CRT lack clinical significance.
Discussion
Our findings strongly suggest that humoral immunity directed against immunodominant tumor antigens or self-epitopes related to ER stress-associated chaperones (CRT) may not contribute to the chemotherapy-mediated control of tumor growth. Using three distinct model systems (B-cell depletion by anti-CD20 antibodies, constitutive Ig deficiency in mMT mice, lack of activatory or inhibitory FcgR resulting from homologous recombination), we demonstrated that B cells or Ig-specific receptors are dispensable for anthracyclinemediated antitumor effects, contrasting with the essential role of T-lymphocyte-mediated immune responses observable in the same settings. Indeed, in these OVA-engineered or wildtype mouse sarcoma models, anthracyclines did not readily mobilize the humoral arm of immunity.
These data do not rule out the possibility that, in other circumstances of dosing or scheduling or other therapeutic regimen, anti-tumor B cell responses could be triggered. Humoral immune responses have been described. Ipilimumab, a fully human mAb directed against cytotoxic However, NY-ESO-1 seropositivity was only predictive of clinical benefit in cases of the concomitant elicitation of NY-ESO1-specific CD8 þ T cell responses. 32 Repeated vaccination with NY-ESO-1 protein in the adjuvants (Montanide plus CpG ODN) induced an integrated Th1 CD4 þ T cell and antibody response against NY-ESO-1 that was eventually completed by CD8 þ T cell immunity. Vaccine-induced antibodies facilitated cross-presentation of NY-ESO-1 epitopes by DCs to CD8 þ T cells. 33 Similarly, therapy-induced antibodies directed against anti-MHC class I-like chainrelated protein A molecules (MICA) enhanced cross-presentation to T cells and immune-mediated antitumor effects. 34 Antibody responses developed towards neovessels following immunization were instrumental to create ischemic tumor necrosis. 35 Hence, GM-CSF-engineered tumor vaccines combined with anti-CTLA4 engendered a co-ordinated cellular and humoral immunity associated with clinically significant tumor regressions in advanced solid cancers. 36 In such regressing tumor burdens, T cell infiltrates were juxtaposed to antibody-producing B cells in long-term responders. Humoral reactivity was reported against proangiogenic cytokines such as angiopoietin-1 and -2 blocking the endothelial cell tube formation and/or macrophage inhibitory factor attenuating macrophage Tie-2 and MMP9 expression. 35 Likewise, antibodies against protein disulfide isomerases (PDI, ERp5, 37 ) or an accessory unit of the vacuolar H þ -ATPase complex 38 appeared of clinical significance. These data are in line with other observations, stating that the presence of tertiary lymphoid organogenesis (TLO), high endothelial venules (HEV) or germinal centers (GC) residing around the tumor nests are associated with good prognosis in breast carcinoma, non-small cell lung cancer and melanoma. [39] [40] [41] [42] Although some particular chemotherapy regimens elicit a therapy-relevant T cell immunity, they fail to ignite protective B-cell responses, at least in mouse sarcomas and human breast cancers, which however, have been investigated at a relatively early time points. Further in-depth investigation should address antitumor serum reactivities in clinical cases, where TLO or HEV or GC are observed post chemotherapy.
We found that anti-CD20 antibodies did not affect the efficacy of anthracyclines. As a caveat, it should be noted that a subset of regulatory CD5 þ CD1d high IL-10 producing B cells (B1 cells) fails to be depleted by anti-CD20 antibodies. 43 Interestingly, the secretion of autoantibodies is a function exclusive to the B1 subset, and the majority of human cancer patients mount specific autoantibody responses against their tumors. 44 Moreover, the population of CD20-resistant B cells has been reported to enhance A20 lymphoma growth in an IL-10-dependent manner. 19 Future studies must evaluate, in which particular settings B1 cells may modulate the growth of human tumors. FcgR (CD64 and CD16) have been shown to have a positive role in the treatment of mouse melanomas with specific antibodies. 45 These preclinical findings are in accordance with human data showing that single-nucleotide polymorphisms (SNP) affecting the protein structure of FcgRIIIA/CD16A determine the in vivo efficacy of monoclonal ADCC-mediating antibodies (such as rituximab, trastuzumab and erbitux). 46 To our knowledge, the clinical significance of such SNPs has not been reported for anthracyclines or oxaliplatin, supporting the findings reported in this paper.
Antibodies against CRT, a Ca þ -binding ER residing chaperone, represent a diagnostic tool for various infectious, autoimmune and cancer-associated disorders. [47] [48] [49] [50] Interestingly, anti-CRT IgA titers are more useful than anti-CRT IgG levels for detecting mammary, colorectal, hepatocellular and pancreatic carcinomas, alcoholic hepatitis, refractory celiac disease or primary biliary cirrhosis. 30, [51] [52] [53] High concentrations of anti-CRT IgA antibodies were more frequently detected in lymph node-positive breast cancers than IgG antibodies, but failed to correlate with CRT membrane expression. 30 The biological significance of anti-CRT antibodies is unclear. However, experimental immunization against CRT could induce liver focal necrosis and hepatitis. 54 Trypanosoma cruzi CRT is highly immunogenic and exhibits cross-reactivity with isogenic cardiomyocytes, thus causing a local autoimmune reaction relevant to Chagas disease. 55 The observation that anti-CRT IgA or IgG serum levels did not significantly increase after anthracycline-based chemotherapy of breast cancer patients may reflect the inability of many tumors to translocate CRT to the cell surface, 56, 57 defects in other hallmarks of ICD such as absent expression of HMGB1 (Yamazaki T et al., In Press), or deficient autophagy, 58 or the general irrelevance of humoral responses to clinical outcome. Future studies must correlate the therapyinduced raise in anti-CRT IgA antibodies or other immunological alterations, including changing frequencies in tumor antigen-specific T lymphocytes, with tumor cell-intrinsic, ICD-relevant parameters.
Materials and Methods
Mouse strains. All the mice were bred and maintained according to both the FELASA and the Animal Experimental Ethics Committee Guidelines (Val de Marne, France). WT SPF C57Bl/6J mice were obtained from Harlan. OT-1 C57Bl/6J mice and Ly5.1 congenic mice were obtained from Jackson Lab, (Bar Harbor, ME, USA). C57Bl/6J FcgRI À / À mice, 23 FcgRI/IIIA/IV ('FcgRIIB-only'), 26 FcgRIII À / À mice, 22 FcgRIV À / À mice, 24 and FcgRI/IIB/III FceRI/II (5KO, also known as 'FcgRIV-only') mice 25 have been reported previously and bred at the Institut Pasteur animal facility. C57Bl/6J mM KO mice were obtained from Centre d'Elevage d'Orléans (Dr Ryffel) and bred at the Institut Gustave Roussy animal facility.
Reagents and antibodies. Doxorubicin was purchased from Sigma-Aldrich (St Louis, MO, USA). Anti-mouse antibodies for CD3e (145-2C11), CD4 (GK1. Tumor-infiltrating lymphocytes analyses. At indicated time points, tumors were harvested, cut into small pieces and digested in Liberase TM 25 mg/ml (Roche, Boulogne Billancourt, France) and DNase I 150 U/ml (Calbiochem, Millipore, Molsheim, France) for 30 min at 37 1C. Single-cell suspension was obtained by crushing the digested tissue with a syringe plunger and filtering through a 100-mm cell strainer. After washing, cells have been used for subsequent immunostaining.
In vivo cell depletion. At indicated time point, MCA 205 OVA tumor-bearing mice received a single 250 mg of anti-CD20 (MB20-11)or IgG2a control i.v, as previously described. 59 B-cell depletion was checked in the spleen and tumors from the antibody administrated mice. CD8 þ T cells have been depleted by using anti-CD8a Ab (53-6.72, Bioxcell, West Lebanon, NH, USA) or Rat IgG2a control (2A3, Bioxcell). The depletions have been started 1 day prior chemotherapy treatment and maintained during the whole experiment. Mice received 100 mg of Ab in 100 ml of PBS, i.p, every 3 days. T cell depletion was checked in the spleen and tumor from the antibody administrated mice.
Mouse anti-OVA Ig dosing. MCA 205 OVA-bearing mice have been treated or not with doxorubicin at day 7 post-tumor inoculation. Two to three weeks later, sera were collected and the presence of OVA-specific IgG, IgA and IgM was determined by using mouse anti-ovalbumin Igs (total G þ A þ M) ELISA kit (alpha diagnostic, Interchim, Montlucon, France), according to manufacturer's instructions.
Patients' cohort. Breast cancer patients who has signed an informed consent for investigations of research purposes were selected from a database of 591 patients who received preoperative anthracyclines-based chemotherapy regimen (plus or minus taxanes and herceptin for HER2 BC) at the Institut Gustave Roussy between 1987 and 2003 (Table 1) . Pathologic complete response (pCR) was defined as the absence of any invasive cancer or isolated tumor cells only in the breast and lymph nodes after completion of chemotherapy. Serum was drawn for CA15.3 dosages and the remaining material kept frozen for parallel investigations, including anti-CRT IgG/A concentration assessments. Therefore, serum withdrawn at diagnosis before chemotherapy, during the 8 cycles of therapy and/or after completion of neoadjuvant treatment at follow up consultations was kept at À 20 1C until ELISA was performed.
Human Anti-CRT IgG dosing. Human anti-CRT IgG and IgA sera concentrations have been evaluated as previously described. 60 Antibody response against CRT has been assessed in a cohort of 63 breast cancer patients and 75 healthy volunteers. The cut-off values for Ig were as follows: detection threshold of 30 UI/ml for IgA and 100 for IgG.
Statistical analyses. Results are expressed as mean ± S.E.M. All experiments were repeated at least twice, yielding similar results. Normal distributions were compared by unpaired, two-tailed Student's t-tests. Statistical analyses were performed by means of the software Prism 5 (GraphPad, San Diego, CA, USA) and P-valueso0.05 were considered as statistically significant.
